Targeting of chondroitin sulfate glycans

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9932375
SERIAL NO

15285830

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • VAR2 PHARMACEUTICALS APS

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Clausen, Thomas Mandel Copenhagen, DK 5 0
Dahlback, Madeleine Swedala, SE 4 10
Daugaard, Mads Vancouver, CA 8 10
Nielsen, Morten Birkerod, DK 19 519
Salanti, Ali Bronshoj, DK 12 19
Theander, Thor Grundtvig Greve, DK 7 25

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 3, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 3, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00